News ReleaseView printer-friendly version
Use of Quidel QuickVue(R) Rapid Flu Test in Nursing Homes Allows for More Rapid Recognition of Outbreaks and Appropriate Therapies
Outbreak Duration and Incidence Rate Lowered in Study Facilities
SAN DIEGO--(BUSINESS WIRE)--Oct. 8, 2007--Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, announced today that a poster presentation at the Infectious Diseases Society of America 45th Annual Meeting (October 5, San Diego) indicated the on-site use of rapid influenza tests allows for the early detection of influenza, more timely treatment of residents (patients), and improved management of respiratory outbreaks in nursing home facilities.
The study, entitled "Active surveillance and Point-of-Care testing (POCT) allows early intervention for influenza outbreaks in nursing homes," was presented by Dr. Dominic Dwyer, MD, FRCPA, of the Centre for Infectious Disease and Microbiology Laboratory Services, ICPMR, Westmead Hospital, Australia. Dr. Dwyer reported on the results from the first two years of an ongoing three-year study. During this period, there were six confirmed influenza outbreaks in the nursing homes. A comparison of outcomes at nursing homes receiving active surveillance with rapid tests and intervention with antivirals versus those with routine self-reporting of outbreaks (with no rapid tests) showed a significant difference in outcome. The attack rate of residents was reduced from 42% to 21%, the time between initial outbreak and intervention with antivirals was reduced by almost 50%, and the duration of the outbreak within the nursing homes was reduced from an average of 22 days to 11.5 days.(1) Dr. Dwyer concluded that "the QuickVue test for influenza performed by nursing home nurses on-site is sensitive and highly specific and allows for rapid recognition of outbreaks and (timely) intervention with antiviral therapy."
"I congratulate Dr. Dwyer on his work with the elderly nursing home population," said Caren Mason, president and CEO of Quidel. "The significant reductions in resident attack rate, and in the duration of the nursing home outbreaks, support the notion that active surveillance with rapid tests coupled with timely intervention with antiviral therapy can have a major impact on health outcomes for these elderly patients. This is particularly important when considering the fact that approximately 90% of the 36,000 persons who die from influenza each year in the United States are among the elderly."(2)
According to the Centers for Disease Control (CDC), influenza is responsible for about 36,000 deaths and more than 200,000 hospitalizations in the U.S. each year. The National Foundation of Infectious Diseases, in a report released in September 2007, indicates that influenza can be especially severe for those with high-risk conditions (e.g., diabetes and heart disease), and recent studies have also found that the illness may trigger up to 92,000 cardiac deaths per year nationwide.(3)
About Quidel Corp.
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com, www.flutest.com, or www.colorectal-test.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, seasonality, the length and severity of cold and flu seasons, uncertainty surrounding the detection of novel influenza viruses involving human specimens, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, technological changes and uncertainty with research and technology development, including any future molecular-based technology, the reimbursement system currently in place and future changes to that system, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration (the "FDA"), intellectual property, product liability, environmental or other litigation, required patent license fee payments not currently reflected in our costs, potential inadequacy of booked reserves and possible impairment of goodwill, and lower-than-anticipated sales or market penetration of our new products. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" in reports and registration statements that we file with the SEC from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision or update of the forward-looking statements.
(1) Poster presented October 5, 2007, IDSA, San Diego, CA on file at Quidel Corporation.
(2) CDC News Conference Transcript, October 24, 2003.
(3) National Foundation for Infectious Diseases, September 20, 2007.
CONTACT: Quidel Corporation
John Radak, Chief Financial Officer, (858) 552-7962
Lippert/Heilshorn & Associates
Don Markley, (310) 691-7100
SOURCE: Quidel Corporation